Agios Pharmaceuticals CLO James Burns Equity Award Transactions

This Form 4 filing reports equity transactions by James William Burns, Chief Legal Officer of Agios Pharmaceuticals, Inc. On June 18, 2026, Burns received 3,000 restricted stock units (RSUs) and had 3,000 performance share units (PSUs) become earned based on achievement of a research milestone. The PSUs were originally granted on March 1, 2025, with vesting contingent on achieving clinical and research milestones. The compensation committee determined that the specified research milestone was met as of June 18, 2026, making those shares eligible to vest on December 31, 2027, subject to continued service. Following these transactions, Burns holds 9,000 PSUs and 3,000 RSUs. The filing represents standard executive compensation activity rather than open market transactions, with all awards granted at $0 cost as typical for equity compensation programs.